Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0
|
作者：
Deangelo, Daniel J. [1 ]
Chen, Ying [2 ]
Cassaday, Ryan D. [3 ,4 ]
Hibma, Jennifer [2 ]
Yang, Derek Z. [2 ]
Garrett, May [2 ]
Zhang, Fan [5 ]
Dimitrov, Svetoslav H. [6 ]
Vandendries, Erik [7 ]
Kantarjian, Hagop M. [8 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[2] Pfizer, San Diego, CA USA
[3] Univ Washington, Seattle, WA USA
[4] Fred Hutchinson Canc Ctr, Seattle, WA USA
[5] Pfizer, Shanghai, Peoples R China
[6] Pfizer, New York, NY USA
[7] Pfizer Inc, Cambridge, MA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-194244
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：732 / 733
页数：2
相关论文
共 50 条
  • [41] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
    Pennesi, Edoardo
    Michels, Naomi
    Brivio, Erica
    van der Velden, Vincent H. J.
    Jiang, Yilin
    Thano, Adriana
    Ammerlaan, Anneke J. C.
    Boer, Judith M.
    Beverloo, H. Berna
    Sleight, Barbara
    Chen, Ying
    Vormoor-Buerger, Britta
    Rives, Susana
    Bielorai, Bella
    Roessig, Claudia
    Petit, Arnaud
    Rizzari, Carmelo
    Engstler, Gernot
    Stary, Jan
    Bautista Sirvent, Francisco J.
    Chen-Santel, Christiane
    Bruno, Benedicte
    Bertrand, Yves
    Rialland, Fanny
    Plat, Genevieve
    Reinhardt, Dirk
    Vinti, Luciana
    Von Stackelberg, Arend
    Locatelli, Franco
    Zwaan, Christian M.
    LEUKEMIA, 2022, 36 (06) : 1516 - 1524
  • [42] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Thomas E. Delea
    Xinke Zhang
    Jordan Amdahl
    Diana Boyko
    Franziska Dirnberger
    Marco Campioni
    Ze Cong
    PharmacoEconomics, 2019, 37 : 1177 - 1193
  • [43] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Delea, Thomas E.
    Zhang, Xinke
    Amdahl, Jordan
    Boyko, Diana
    Dirnberger, Franziska
    Campioni, Marco
    Cong, Ze
    PHARMACOECONOMICS, 2019, 37 (09) : 1177 - 1193
  • [44] Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
    Savoy, J. Michael
    Welch, Mary Alma
    Nasnas, Patrice E.
    Kantarjian, Hagop
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (12) : 347 - 356
  • [45] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
    Edoardo Pennesi
    Naomi Michels
    Erica Brivio
    Vincent H. J. van der Velden
    Yilin Jiang
    Adriana Thano
    Anneke J. C. Ammerlaan
    Judith M. Boer
    H. Berna Beverloo
    Barbara Sleight
    Ying Chen
    Britta Vormoor-Bürger
    Susana Rives
    Bella Bielorai
    Claudia Rössig
    Arnaud Petit
    Carmelo Rizzari
    Gernot Engstler
    Jan Starý
    Francisco J. Bautista Sirvent
    Christiane Chen-Santel
    Benedicte Bruno
    Yves Bertrand
    Fanny Rialland
    Geneviève Plat
    Dirk Reinhardt
    Luciana Vinti
    Arend Von Stackelberg
    Franco Locatelli
    Christian M. Zwaan
    Leukemia, 2022, 36 : 1516 - 1524
  • [46] Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Marks, David, I
    Kebriaei, Partow
    Stelljes, Matthias
    Goekbuget, Nicola
    Kantarjian, Hagop
    Advani, Anjali S.
    Merchant, Akil
    Stock, Wendy
    Cassaday, Ryan D.
    Wang, Tao
    Zhang, Hui
    Loberiza, Fausto
    Vandendries, Erik
    DeAngelo, Daniel J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) : 1720 - 1729
  • [47] Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review
    Marks, David I.
    Cassaday, Ryan D.
    Ribera, Josep-Maria
    Schuh, Andre C.
    Park, Jae H.
    Chiaretti, Sabina
    Stelljes, Matthias
    EXPERT REVIEW OF HEMATOLOGY, 2025, 18 (01) : 91 - 103
  • [48] Characteristics of Medicare patients with relapsed/refractory acute lymphoblastic leukemia initiating treatment with inotuzumab ozogamicin, blinatumomab, or other agents.
    Russell-Smith, T. Alexander
    Shah, Richa
    Silverstein, Alison R.
    Petrilla, Allison A.
    Leinwand, Brian
    Norris, Diane
    Schroeder, Amy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19009 - E19009
  • [49] Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin
    Cassaday, Ryan D.
    Marks, David I.
    DeAngelo, Daniel J.
    Jabbour, Elias J.
    Advani, Anjali S.
    O'Brien, Susan
    Wang, Tao
    Neuhof, Alexander
    Vandendries, Erik
    Kantarjian, Hagop M.
    Stock, Wendy
    Stelljes, Matthias
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (03) : E77 - E81
  • [50] Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
    Zaina T. Al-Salama
    Targeted Oncology, 2018, 13 : 525 - 532
12345